A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors

被引：0
|
作者：
Sausville, E. [1 ,2 ,3 ,4 ,5 ]
Garbo, L. [1 ,2 ,3 ,4 ,5 ]
Weiss, G. J. [1 ,2 ,3 ,4 ,5 ]
Anthony, S. [1 ,2 ,3 ,4 ,5 ]
Shkolny, D. [1 ,2 ,3 ,4 ,5 ]
Yurkovetskiy, A. V. [1 ,2 ,3 ,4 ,5 ]
Bethune, C. [1 ,2 ,3 ,4 ,5 ]
Fram, R. J. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] New York Oncol Hematol, Albany, NY USA
[3] TGen, Clin Res Serv, Scottsdale, AZ USA
[4] Mersana Therapeut Inc, Cambridge, MA USA
[5] Covance Bioanalyt, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2574
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
    K. Gelmon
    H. Hirte
    B. Fisher
    W. Walsh
    M. Ptaszynski
    M. Hamilton
    N. Onetto
    E. Eisenhauer
    Investigational New Drugs, 2004, 22 : 263 - 275
  • [42] Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors
    Soepenberg, O
    Dumez, H
    Verweij, J
    Semiond, D
    deJonge, MJA
    Eskens, FALM
    ter Steeg, J
    Selleslach, J
    Assadourian, S
    Sanderink, GJ
    Sparreboom, A
    van Oosterom, AT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 889 - 898
  • [43] Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors
    Chen, N.
    Chawla, S. P.
    Chiorean, E. G.
    Read, W. L.
    Gorbaty, M.
    Mita, A. C.
    Yung, L.
    McNally, R.
    Renschler, M. F.
    Sharma, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Phase I study of i.v. vinflunine (VFL), a novel microtubule inhibitor, given every three weeks in Japanese patients with solid tumors
    Mukohara, Toru
    Minami, Hironobu
    Nagai, Shunji
    Nakajima, Hikaru
    Mukai, Hirofumi
    Kitagawa, Koji
    Morinaga, Ryotaro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    CANCER RESEARCH, 2008, 68 (09)
  • [45] Phase I and pharmacokinetics (PK) study of RPR 116258A given as a weekly 1-hour infusion at day 1, day 8, day 15, day 22 every 5 weeks in patients (pts) with advanced solid tumors.
    Fumoleau, P
    Trigo, J
    Campone, M
    Baselga, J
    Sistac, F
    Gimenez, P
    Manos, L
    Fontaine, H
    Semiond, D
    Sanderink, G
    Perard, D
    Besenval, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3710S - 3710S
  • [46] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 129 - 136
  • [47] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Nobuyuki Yamamoto
    Narikazu Boku
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 129 - 136
  • [48] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    H. Murakami
    T. Kurata
    Y. Onozawa
    J. Watanabe
    A. Ono
    T. Takahashi
    N. Yamamoto
    Y. Fujisaka
    H. Kiyota
    H. Hayashi
    K. Tanaka
    K. Nakagawa
    S. Kuroda
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 623 - 630
  • [49] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    Murakami, H.
    Kurata, T.
    Onozawa, Y.
    Watanabe, J.
    Ono, A.
    Takahashi, T.
    Yamamoto, N.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Kuroda, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 623 - 630
  • [50] A phase I study of SB-408075 administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
    Helft, PR
    Schilsky, RL
    Kindler, HL
    Bertucci, D
    Dewitte, MH
    Martino, HK
    Friedman, CJ
    Erickson, JC
    Lambert, JM
    Ratain, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3786S - 3786S
12345